Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas K Price

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Cell Cycle (Georgetown, Tex.)|May 22, 2004
hTert-immortalized endothelial cells: an important new research toolDouglas K Price, William D Figg
Cancer Biology & Therapy|July 16, 2004
Mutations in the EGFR: the importance of genotypingDouglas K Price, William D Figg
Cancer Biology & Therapy|July 10, 2014
Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivationAnjali Srivastava, Douglas K Price, William D Figg
Anti-Cancer Drugs|April 7, 2007
ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancerHaiqing Li, Douglas K Price, William D Figg
Cancer Biology & Therapy|May 6, 2016
YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?Fiorina Kyritsi, Douglas K Price, William D Figg
Cancer Biology & Therapy|December 19, 2006
DNA microarrays: tissue removal and processing affects gene expressionSandra Ockers, Douglas K Price, William D Figg
Cancer Biology & Therapy|March 18, 2016
Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?Crystal R Leibrand, Douglas K Price, William D Figg
Cancer Biology & Therapy|June 2, 2009
VEGF inhibition and metastasis: possible implications for antiangiogenic therapyBevin C English, Douglas K Price, William D Figg
Cancer Biology & Therapy|June 29, 2010
Genetic variant associated with aggressive not indolent prostate cancerC Tyler Kirkland, Douglas K Price, William D Figg
Cancer Biology & Therapy|November 20, 2010
Prostate cancer genomic signature offers prognostic valueSarah M Troutman, Douglas K Price, William D Figg
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Cell Cycle (Georgetown, Tex.)|May 22, 2004
hTert-immortalized endothelial cells: an important new research toolDouglas K Price, William D Figg
Cancer Biology & Therapy|July 16, 2004
Mutations in the EGFR: the importance of genotypingDouglas K Price, William D Figg
Cancer Biology & Therapy|July 10, 2014
Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivationAnjali Srivastava, Douglas K Price, William D Figg
Anti-Cancer Drugs|April 7, 2007
ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancerHaiqing Li, Douglas K Price, William D Figg
Cancer Biology & Therapy|May 6, 2016
YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?Fiorina Kyritsi, Douglas K Price, William D Figg
Cancer Biology & Therapy|December 19, 2006
DNA microarrays: tissue removal and processing affects gene expressionSandra Ockers, Douglas K Price, William D Figg
Cancer Biology & Therapy|March 18, 2016
Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?Crystal R Leibrand, Douglas K Price, William D Figg
Cancer Biology & Therapy|June 2, 2009
VEGF inhibition and metastasis: possible implications for antiangiogenic therapyBevin C English, Douglas K Price, William D Figg
Cancer Biology & Therapy|June 29, 2010
Genetic variant associated with aggressive not indolent prostate cancerC Tyler Kirkland, Douglas K Price, William D Figg
Cancer Biology & Therapy|November 20, 2010
Prostate cancer genomic signature offers prognostic valueSarah M Troutman, Douglas K Price, William D Figg
Pageof 11